PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT04134715
- Locations
- 🇺🇸
Quotient Sciences-Miami, Miami, Florida, United States
🇺🇸Quotient Sciences Screening Office, Coral Gables, Florida, United States
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
- Conditions
- Dermatitis Atopic
- Interventions
- Drug: PF-07038124 or vehicleDrug: PF-07038124 and Vehicle
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT04135560
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
- Conditions
- Gram-negative Bacterial Infection
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT04126031
- Locations
- 🇬🇷
"ATTIKON" University General Hospital, Chaidari, Athens, Greece
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Tufts Children's Hospital at Tufts Medical Center, Boston, Massachusetts, United States
A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04126044
- Locations
- 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT04124653
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇺🇸New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT04115189
- Locations
- 🇧🇷
Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil
🇦🇷Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina
🇦🇷Sanatorio del Salvador - Cordoba, Cordoba, Argentina
A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04111614
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Vyndaqel Capsules Special Investigation (ATTR-CM)
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Drug: Treatment for TTR amyloidosis
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1214
- Registration Number
- NCT04108091
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT04099563
- Locations
- 🇨🇳
Beijing Hospital Sub-Center of Beijing Hospital Clinical Trial & Research Center, Beijing, China
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
- Conditions
- Acne Inversa
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 194
- Registration Number
- NCT04092452
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Dermatology Associates of Seattle, Seattle, Washington, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States